RxSight, Inc. (RXST) Earnings Call Transcript
July 7, 2026
Earnings Call Speaker Segments
Thanks, operator. Joining me this morning are RxSight's President and Chief Executive Officer, Dr. Ron Kurtz, along with our Chief Financial Officer, Mark Wilterding. Two press releases went out from RxSight yesterday: the first covers a new collaboration agreement with Alcon, while the second covers preliminary revenue results for the 3 months ending June 30, 2026, an updated product pipeline, and revised full guidance. Both press releases, plus the corresponding 8-Ks, can be found on the company's website. . Before we get started, I want to let you know that what we say and how we answer questions on today's call represent management's views as of today, July 7, 2026, and will contain forward-looking and opinion statements, such as predictions, estimates, plans, expectations, and other information. Actual results could differ materially from what is expressed or implied due to certain risks and uncertainties. Those risks and uncertainties are described more fully in the press release we issued yesterday and in our filings with the Securities and Exchange Commission, or SEC. We caution investors against placing undue reliance on forward-looking statements, and we disclaim any obligation to update or revise them, except as the law may require. On today's call, we will go over certain non-GAAP financial measures. I'd also like to remind everyone that the preliminary results we discuss today are estimates, and our complete unaudited financial results for the second quarter of 2026, which remain subject to review by our independent auditor, are expected to be announced on Wednesday, August 5, 2026. Please note that an audio replay of this conference call will be available on our Investor Relations website. With that, I'll hand the call over to Ron.
Hello, and thanks for being with us today. For a number of years now, the RxSight team has been working on proprietary hybrid IOL materials intended for next-generation light adjustable technology — materials capable of supporting a complete range of adjustable lenses spanning every premium category, engineered to allow broader patient choice and customization while cutting down on the postoperative treatments required. These efforts are moving forward in two ways: through our stand-alone product pipeline and via our collaboration with Alcon. The quality of vision that has drawn LAL patients to this technology for many years will serve as the foundation for RxSight's next-generation adjustable IOLs. Through our partnership with Alcon, the goal is to draw on the expertise of each company in order to develop adjustable presbyopia-correcting IOLs. That will make it possible, for the first time, for doctors to refine visual outcomes noninvasively following surgery for patients selecting a PCIOL. Considered together, these technology-driven strategic initiatives cement RxSight's standing as the leader in postoperative adjustability, establish a platform for future high-margin growth, and speed up expansion across a wider base of patients. We see these strategic developments as key multiyear growth drivers for RxSight, yet last night's announcement also laid out the near-term challenges we faced in the second quarter, following a number of quarters in which utilization trends were comparatively stable. We don't yet have Q2 data from other premium IOLs, but our belief is that this retrenchment ties back to widespread competitive trialing activity connected to new product launches. The LAL value proposition is still highly differentiated, but these trial programs offer a significant short-term incentive within a practice environment that is already strained. The effects of competitive trialing usually fade as doctors establish the true value of a new offering from their own clinical experience, yet we anticipate that the heightened competitive environment will stay active through the end of the year; we also note that consumer sentiment remained under pressure, which in our view may have led to more deliberate patient decision-making and softer overall procedure activity. Cataract surgery generally cannot be put off indefinitely, but unusual declines in overall cataract volumes showed up in Q1, with patient confidence and the broader economic backdrop being 2 potential factors. Our belief is that we can overcome these challenges by accelerating customer reengagement efforts, which have proven successful in targeted rollouts, and we are excited to be making additional investments in our U.S. LAL sales force so as to expand our depth of penetration within accounts. Alongside our technology's unparalleled clinical outcomes, we remain confident in our team's ability to navigate these headwinds successfully. I'll now turn it over to Mark to provide select financial metrics related to our second quarter performance and updated thoughts on our full year 2026 outlook.
Thanks, Ron. As we said in the press release we put out before the market opened last night, we're looking at second quarter total company revenue of roughly $32 million to $34 million, and that figure includes $5 million to $7 million tied to the RxSight, Alcon strategic collaboration agreement. How much revenue from that agreement we'll actually book in Q2 is still dependent on finishing our quarter end close procedures and accounting assessment. We anticipate wrapping those up before we report second quarter results in August. Preliminary total company sales, leaving out revenue connected to the agreement, came to about $27 million in Q2, which is down 20% from the same period a year ago. During the quarter, LAL units totaled 24,917, down 10% compared to the same period last year, reflecting the same challenges Ron mentioned earlier. Eleven LDDs were sold by the company, and one LDD rental unit was placed, which lifted our installed base to 1,166 units. Because of the revenue effects tied to the collaboration agreement, together with preliminary second quarter sales, we are revising our full year 2026 outlook. Our updated expectation for full year 2026 revenue is now $140 million to $160 million. Within that range, RxSight sales account for $110 million to $120 million, while revenue recognized from the RxSight, Alcon strategic collaboration contributes $30 million to $40 million. The guidance for RxSight sales assumes the second quarter headwinds will persist. The way revenue from the collaboration agreement works is set out in the terms and conditions of the 8-K we submitted to the SEC yesterday evening. Because of the better-than-expected mix of LALs relative to LDDs that we sold during the second quarter, along with our confidence that this pattern will hold through the rest of 2026, our updated outlook for full year gross margin is now 73% to 75%, compared with the 70% to 72% we guided to before. Despite the growing investments Ron described earlier in our LAL sales force and the sizable costs tied to the collaboration agreement we announced recently, our expectation for operating expenses remains unchanged: we still see them landing at the high end of the $150 million to $160 million range, consistent with prior guidance. Our cash position, including cash equivalents and short-term investments, came to roughly $209 million at the close of the quarter. Ron, I'll now hand things back over to you.
Thanks, Mark. Before we get to Q&A, I'd like to express appreciation to my colleagues at RxSight and to the numerous partners we work with in clinical practice who, day in and day out, are making cataract surgery results better by giving patients the ability to fine-tune and tailor their vision once the procedure is done. What we're announcing today underscores 2 ways we keep pushing that mission forward; near term, by stepping up our commercial and clinical reengagement work even more, so that a greater number of patients can reach the top-tier, exact, customized clinical outcomes that have by now been shown across multiple real-world and clinical study settings with the current generation of LAL technology. Over the medium to longer horizon, by carrying on with innovation in adjustability, something our team has focused on for a long time. Beyond next-generation LAL and LAL+, we're also developing LAL Toric, a new lens built to merge toric correction that's built in with postoperative refinement of residual sphere and cylinder. Every one of these IOLs is engineered to preserve the highest levels of visual quality and adjustability while at the same time enabling better workflow and reducing the number of postoperative treatments needed. Our work with Alvin creates a new avenue for innovation in the PCIOL space, giving doctors and patients greater precision and confidence. Although there are financial benefits from the agreement in both the near term and the long term, we see this collaboration as further validation of our technology platform and intellectual property, along with the wider opportunity that adjustability presents in cataract surgery. Considered as a whole, these development initiatives show our ongoing dedication to doctors and practices. Through building a family of adjustable premium IOLs that can be matched to what patients need, our customers are able to draw on both the knowledge investments they've already made to become experts in postoperative adjustability and their capital investments in the light delivery device, or LDD. RxSight came into the cataract market with a fundamentally different approach and a genuinely novel technology, and in a relatively short span of time we proved the clinical value of adjustability and built a strong position in the premium cataract market. With that foundation in place, these next-generation developments and adjustability offer meaningful opportunities for additional growth; and with that, I'll have our operator open the call for questions.
Could you hear me okay, Ron?
Yes.
Thanks. I had 2 questions about technology — the new technology — one regarding Alcon and another about the internal products you mentioned. So to begin with Alcon, it sounds like you're essentially pairing your light adjustable technology with their trifocal and EDOF lenses. So what I'd like to know is what are the technology challenges involved in that? Put differently, what has to be done to make that happen? And what benefits will result? What do you expect those benefits to be? And any detail on the time lines? And I had one follow-up.
So let's begin with the benefits. The reason we both believe this is a good idea. I think if you examine the reasons outcomes or patients might be dissatisfied following PCIOLs, residual refractive error sits at the top of that list. So being able to optimize visual acuity after surgery through a noninvasive light treatment, we believe will be a significant addition to PCIOL technology. As for the time frame, we haven't set that out except to say we believe it falls within our planning period, which is typically in that 5-year period. I there are a number of technical and regulatory efforts that will be part of this collaboration. Those — clearly, we've completed some prework to bring us to this stage, and we feel good about our ability to deliver on the promise of this collaborative effort.
That's useful. Then, Ron, regarding those internal products you mentioned, when should we expect the next-generation LALs? And what exactly does better workflow and fewer post-op treatments needed mean — for instance, by how much do you believe post-op treatments can be cut?
The way we've framed it is that we'd anticipate these developments happening in the mid-range of our planning period. So that's — we'll keep refining that as time goes on. And obviously, each of the efforts will have its own individual time lines. In — and I apologize, your second question was...
So, how much — what does improved workflow and fewer necessary postoperative treatments actually mean? To what extent might you be able to cut down on the post-op treatments?
If we take a look at how many treatments are being used right now. Typically, you're looking at roughly 1.5 up to slightly more adjustments, plus on average, around 2 walk-in treatments. We think that by offering the possibility of a single lock-in, we would clearly see a substantial decrease in the treatments needed. Beyond that, the instances where additional adjustments are needed tend to be tied to greater degrees of the stigmatism. So if we can deliver some built-in astigmatism, that could potentially bring it down as well; therefore, we believe there could be a quite meaningful drop in how many treatments are required.
I'd like to ask a couple more things, picking up where Larry left off, but focused on the tech side. When you consider the lens and the work with Alcon, RxSight went through a PMA. There were clinical trials tied to that. Do you expect something similar would be required with their existing set of lenses, so that a product could reach the market combining both your technologies and theirs?
We haven't said anything about the particular regulatory route we intend to pursue. Clearly, that's something we'll be working on together with Alcon; and once again, we believe there's a solid track record for both technologies. And clearly, our plan would be to build on that strong foundation as well.
All right. Then there's another thing, Ron — and yes, perhaps I'm getting ahead of myself — but what about how you'd price something in the PCIOL category? If we look at what physicians currently pay for PanOptix, and then consider what the LAL costs right now, both sit at the top end of the range that PCIOLs can reach. Combining those 2 technologies, my guess is you might raise that pricing ceiling, so to speak. So I'd love to hear your view on whether that's realistic, what the value would be of a merged technology, and how you'd approach setting an initial price compared with where the PCIOL market stands today.
Sure, those are excellent questions. My sense is they're really about what happens down the road, and mostly they're Alcon's to answer. That said, let me focus on the value side, which is this: we'd be offering patients state-of-the-art optical designs plus the capacity to fine-tune refractive error after surgery, without an invasive procedure; that's a degree of certainty nobody has right now. So how much is that worth to physicians and to patients? I believe the market is going to settle that; though typically, residual refractive error is what gets named as the issue with PCIOLs.
I just wanted to ask how you arrived at the conclusion that a strategic collaboration agreement was the best route, rather than other strategic possibilities such as selling, and also how you view the partnership as opening the door to further collaboration with Alcon or a possible acquisition.
Well, we believe this is an excellent way for us to create value in RxSight at this moment, drawing on not just our technology for our own pipeline, but drawing on it as well for an area where we don't currently take part, specifically the PCIOL space. And by doing that alongside a market leader and without doing it well, we're able to keep a very positive balance sheet. So all of these, I think, are positives for the collaboration. Obviously, we have to execute on all these efforts and with the collaboration with Alcon, but we feel confident in our ability to do that and in building our core LAL business as well.
Understood. Next, I'd like to ask a bit more about those preliminary Q2 results. My understanding is that you'd been anticipating a certain amount of competitive trialing. So what is it about the trialing activity you're observing that has perhaps made these headwinds more severe than anticipated? Beyond that, what has been incorporated into the overall guide when it comes to competitive trialing, along with other elements you referenced, such as consumer sentiment?
Sure — perhaps I'll begin at a broader perspective, and then Mark, please jump in if you'd like. The way I see it, competitive trialing programs have emerged at a level we might not have completely expected. Part of the reason could be that a second major player now offers products across both the trifocal and EDOF categories, which has the potential to intensify competition overall in this space, and our assumption is that this will persist through the balance of the year. Ultimately, what sets the LAL apart is our ability to fine-tune vision so that binocular vision is optimized for patients — something these competing technologies simply cannot achieve. Our belief is that this will prove to be a major point of differentiation and central to our success. And Stephanie, regarding guidance for the rest of the year, Ron just touched on this, but my sense is that we expect this competitive landscape to stay active right up to year-end. That is the assumption built into the guidance we issued today.
Perhaps I could ask one more thing regarding our outlook, particularly the LDD projections. My understanding is that earlier you anticipated 25 each quarter, yet only 12 materialized. And I've heard what was said about trials from competitors. That said, what is the situation with the LDD pipeline? Has anything shifted in a significant way during May and June regarding that?
Over the near term, my view is that trials from rivals could have had an effect, and likely did, simply because when a practice receives the chance to work with a certain quantity of lenses, that might cause them to be less intent on adopting something new such as an LDD, which could push back that choice. Plenty of interest remains when it comes to purchasing this technology, though we believe some influence came from that. Additionally, our report mentioned that a single LDD was rented by us. Never before had we done something like that. In our view, this could serve as a strong method for bringing the technology in, particularly beyond the U.S. Naturally, that postpones when revenue is recognized, yet it may allow us to push our OUS opportunity even harder.
All right. And moving to the commercial pivot or strategy side of things. With this increased competitive trialing, maybe you could just provide an update on that. Do you have to alter anything about that initiative? And regarding the commercial investments you mentioned in the script, I mean, is it simply adding headcount? Or are there other things you're doing there?
Well, there are definitely combined efforts involving both having additional resources so that we can go deeper with our large installed base, but also fine-tuning the techniques that, that team utilizes. So it's a combination of factors. And we're — again, we — despite the challenges that we had in Q2, we — our team remains very confident in their ability to overcome those, and we're looking forward to that in future quarters.
Ron, I believe you mentioned previously that patients receiving LAL have arrived at roughly equal rates from those who'd have gotten a monofocal toric or a multifocal lens. So in your view, how should the Alcon collaborative lens be positioned relative to the blended vision available now for correcting presbyopia? I'm curious whether an adjustable PCIOL would be additive or cannibalizing over the long term, assuming it gains approval.
Let me clear that up a little, Steve. What our data indicates is that the great majority of LAL patients originate from either monofocal or monofocal toric, with fewer than 1/4 coming from the PCIOL — and that figure combines both EDOF and trifocal. Consequently, the overlap is fairly minor. This is a segment where we haven't played a role. And we believe that by providing a differentiated product alongside Alcon in that segment, we can do more than just reach a large number of patients. So previously we weren't serving them with adjustability, but we could potentially expand that market too. It's comparable to our experience in the monofocal and monofocal toric segment, where we drew new patients into the premium space.
All right, that's useful. And now, as a follow-up to what was asked before: I realize you're clearly not going to discuss figures for 2027, but what makes you confident that the commercial efforts you've been implementing can contribute to better growth in the coming year? And how much can you leverage this greater intensity in the sales force?
As we've mentioned before, we've run certain focused initiatives, and we've started to see some initial outcomes from them, which is part of what we're broadening here — through growing our sales team. So it draws on what we've learned, and also on what our team has learned and how our team evaluates things at each individual account. So once more, we'll stay focused on this for the rest of this year, and going into '27; yet we believe that ultimately, the clinical outcomes that our technology produces — which, I should point out, are increasingly being supported in peer-reviewed journals. There are multiple publications — multiple publications in recent editions of the leading cataract journal, Journal of Cataract and Refractive surgery; and this keeps building the narrative around quality of vision and customization of vision for LAL.
All right, that's great. I suppose I'm just a bit curious — when it comes to ASP trends during 2Q, is there anything worth flagging on the LDD side or the LAL side? And are you building in any shifts as you look ahead to the remainder of the year?
Young, this is Mark. From an ASP standpoint, nothing meaningful changed in the second quarter for either LDDs or LALs. Our expectation is that LALs stay quite steady. With LDDs, as we discussed during last quarter's call, we're assuming that ASP might decline somewhat gradually, which is typical for capital equipment, and also given that some OUS sales and rentals get included over time.
All right, understood. That's quite useful; and now I suppose I have one regarding the P&L. The OpEx guidance, as I understand it, stayed the same on the whole. Still, I'm just somewhat interested, since we're talking about the collaboration and the R&D percentage, how much expansion or adjustment will be needed going forward from where we are now?
Over the coming several months, quarters, and years, we'll be collaborating closely with our partners at Alcon to determine precisely what that ends up looking like; but — the truth is, at this moment I lack complete visibility into it. Clearly, this is a multiyear collaboration agreement aimed at developing a genuinely unique product that does not exist today. Accordingly, a substantial level of investment will be directed toward it, yet it's difficult for me to put a number on that right now, at this stage of the agreement.
Great. To start, I want to touch on competitive trialing. It seems like this topic keeps coming up again and again; and there's more — clearly, additional U.S. innovation headed our way with Galaxy, and WD Pro probably arriving within the next 12 months. And definitely, more lenses after those. So Ron, perhaps for you, is there something RxSight can do, or is there something specific you're looking into to, I suppose, maybe handle these trialing headwinds going forward?
Well, clearly, for those who are pursuing it, it isn't a long-term strategy; it does — at minimum, it's not sustainable. So I believe it is, eventually, self-limited. That said, I think what we can do is simply present the strongest case possible grounded in data with our practices, with our doctors, and with potential patients regarding the advantages of having — and the confidence that comes from — adjustability. There's — each — if you look back at the industry's historical trends, they've generally shifted toward less of what I'd call less multifocality, because of the side effect profiles. And so you've got — you've witnessed that in both the trifocal space and the EDOF space. The other side of that is that this leads to less near vision. And so the manner in which we can balance vision in both eyes. Doctors are able to balance vision in both eyes through our technology in ways tailored to that particular patient's daily activities, to their neurological system and optical system, which is quite unique. And so as time goes on, we believe that this differentiation is our strongest lever in tackling what are otherwise, in my view, less critical factors tied to these trialing efforts.
Understood. That tracks. Now, shifting over to the Alcon partnership. I suppose it's clear that correcting residual refractive error without an invasive procedure using a PCIOL does carry value. Still, my sense is that with fixed multifocals, LASIK touch-ups happen fairly often. So Ron, could you walk through why surgeons might want something other than what seems like a fairly established method — multifocals followed by laser treatment?
What I'd say is that until another option exists, folks tend to be content with how things are. LASIK, after all, means going through surgery a second time. A broad range of complications and risks may accompany it, dry eye among them — and in this group of patients, an older group, that can be especially troublesome. So when given an option, I believe both patients and physicians would pick something noninvasive, particularly something letting them step in when residual refractive error is far smaller, thanks to that reduced risk profile, or lesser degree of invasiveness. So it seems to me this offers flexibility. And as I said before, with PCIOL technology trends moving toward less multifocality, what you frequently observe — on the EDOF side in particular — is pairing those with differing refractive corrections for each eye. With a fixed IOL, though, the surgeon must set that in advance, whereas an adjustable PCIOL can be experienced by the patient after the operation and tuned together with the patient. Quite a different — quite a different process, and in our view a possible result that will hold substantial value.
Appreciate it, operator. We're eager to share more updates when we hold our usual second quarter 2026 conference call at the start of August. That's all — take care.
This concludes today's conference call. You may now disconnect. Have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete RxSight, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to RxSight, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.